Drug Database
AZ

azithromycin (Azimac)

✓ Approved

Beijing Holley-Cotec Pharma · 小分子 · 小分子

什么是 azithromycin?

azithromycin 是一种小分子,由Beijing Holley-Cotec Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Azimac
公司Beijing Holley-Cotec Pharma
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

azithromycin 针对 8 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsSinusitis✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedPloS one2026-11-18

Intrapartum oral azithromycin versus placebo alone or in combination with other antimicrobials on maternal infection in South East Asia.

Patel Archana B AB, Kurhe Kunal K, Bhargav Savita S, Khedikar Vaishali V et al.

In low-resource facilities that routinely use intrapartum prophylactic antimicrobials, the use of multiple antimicrobials could be rationalised by a single oral dose of oral azithromycin. The Azithromycin Prevention in Labor Use Study (A-PLUS), a randomized double-blind, placebo-controlled trial performed across eight sites in seven countries amongst women who planned to deliver vaginally. They were randomly assigned to receive study drug, a single intrapartum 2 gm oral dose of azithromycin or an identical appearing placebo. Data from four South-East Asia sites (Indian sites Nagpur and Belagavi, Pakistan, and Bangladesh) was analyzed to evaluate whether the use of non-study antimicrobials (alone or in-combination) given after randomization through one-day postpartum for any indication (prophylactic or treatment) modified the effect of study drugs on maternal outcomes (maternal infections, antibiotic usage 2-42days postpartum on ambulatory basis or re-hospitalization). The non-study antimicrobials given after randomization through 1-day postpartum was defined by four exposure sub-groups within azithromycin and placebo arm as, Use of: i) No non-study antibiotic; ii) Cephalosporin only; iii) Other non-study non-cephalosporin antibiotics; and iv) Cephalosporin and other non-study non-cephalosporin antibiotics. An intent to treat (ITT) analysis was adopted. Adjusted relative risks and 95% confidence intervals comparing azithromycin with placebo were estimated using Poisson regression models with robust variance estimators that included study site, maternal non-study antimicrobial use, and a treatment-by-non-study antimicrobial use interaction term. All maternal non-study antibiotic subgroups had balanced randomization between azithromycin and placebo. The risk of any maternal infections was reduced when only azithromycin was received versus placebo (RR = 0.75; 95% CI-0.57-0.98) and when group iv antimicrobials were used with azithromycin compared to only group iv antimicrobials (RR = 0.79; 95% CI-0.66-0.95). The use of antibiotics from day2-42 was similar in both arms (azithromycin or placebo) with or without use of other antimicrobials. This secondary analysis found no evidence that non-study antimicrobials use modified the effect of azithromycin on maternal outcomes. This study underscores the importance of considering an easily administrable intrapartum prophylaxis of oral monotherapy in low resource, high risk for infections sites to reduce antimicrobial resistance due to multiple antimicrobial use.

PMID 43050477
阅读全文 →
PubMedJCEM case reports2026-11-18

Transient hypoparathyroidism and symptomatic hypocalcemia complicating babesiosis.

Amer Bushra B, Phillips Brian B

Babesiosis, caused by Babesia microti, is a tick-borne intraerythrocytic infection with diverse manifestations, but endocrine complications are rarely reported. We describe a 60-year-old man who presented with fever, chills, and cognitive symptoms and was diagnosed with babesiosis by peripheral smear, serology, and polymerase chain reaction. Despite improvement with atovaquone and azithromycin, he developed confusion, paresthesia, and fatigue, prompting further investigation. Laboratory testing revealed hypocalcemia (total calcium, 6.8 mg/dL [SI: 1.7 mmol/L]; reference range, 8.4-10.4 mg/dL [SI: 2.10-2.60 mmol/L]); ionized calcium, 3.8 mg/dL (SI: 0.95 mmol/L; reference range, 4.7-5.5 mg/dL [SI: 1.17-1.37 mmol/L]), a low parathyroid hormone concentration of 9 pg/mL (SI: 9 ng/L; reference range, 18-88 pg/mL [SI: 1.9-9.3 pmol/L]), and hyperphosphatemia, with phosphate concentration of 5.7 mg/dL (SI: 1.84 mmol/L; reference range, 2.5-4.5 mg/dL [SI: 0.81-1.45 mmol/L]), consistent with hypoparathyroidism, with normal magnesium and vitamin D levels. Other etiologies were excluded. He was treated with intravenous calcium followed by oral calcium and calcitriol, resulting in symptomatic and biochemical improvement. Serial monitoring demonstrated gradual recovery of parathyroid function, allowing discontinuation of calcitriol. At follow-up, calcium, phosphate, and parathyroid hormone normalized, and symptoms resolved. This case describes transient hypoparathyroidism associated with babesiosis, with possible cytokine- or immune-mediated mechanisms.

PMID 43047671
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Epidemiology and Treatment Challenges of Acne, With Insights Into the Role of Dermocosmetics: An Expert Consensus From India-A Modified Delphi Method.

Sachdev Mukta M, Madnani Nina N, Kohli Malavika M, Lahiri Koushik K et al.

Acne vulgaris is a common skin condition that typically begins in adolescence but can often persist in adulthood, contributing to significant physical and psychosocial burden. Despite the availability of multiple treatment options, challenges such as poor adherence, treatment-related side effects, and post-inflammatory hyperpigmentation remain common in clinical practice. Dermocosmetics are increasingly used in acne management, either alone in mild cases or as adjuncts to medical therapy. To assess acne prevalence, treatment practices, and key management challenges, along with the role of dermocosmetics, based on expert consensus from India. A panel of 10 dermatologists participated in a modified Delphi process comprising a pre-meeting survey followed by a structured advisory board discussion, capturing clinical practice patterns, treatment approaches, and perspectives on dermocosmetic use in acne management. Experts reported treating a high number of acne patients, primarily adolescents, with a higher proportion of females. Hyperpigmentation and scarring were common sequelae of acne, while treatment adherence and antibiotic resistance, particularly to erythromycin and azithromycin, were noted as key challenges. Procedural interventions, including chemical peels, lasers, and comedone extraction, were increasingly used in early acne management, especially in patients prone to post-inflammatory hyperpigmentation and relapse. Low-dose isotretinoin and hormonal therapies were commonly used in acne management, while dermocosmetics were utilized as monotherapy in mild cases and as maintenance therapy following treatment in more severe cases. Lifestyle factors such as high glycaemic diets, whey protein, multivitamins, and steroid-like drugs were identified as potential contributors to acne exacerbation. Findings are based on a small expert panel convened with industry support and reflect clinical opinion rather than primary patient data. Procedural interventions are becoming more popular, thereby providing an opportunity to incorporate dermocosmetics into acne treatment regimens.

PMID 43047076
阅读全文 →
PubMedWorld journal of pediatrics : WJP2026-11-18

Expert consensus on the diagnosis and treatment of recurrent wheezing in preschool children.

Zhang Yuan-Yuan YY, Tang Lan-Fang LF, Wang Ying-Shuo YS, Bai Guan-Nan GN et al.

Wheezing is a very common symptom in preschool children. Compared with that of older children with wheezing or asthma, the morbidity and health care utilization of preschool are disproportionately high, imposing a heavy economic burden on the health care system and society. Furthermore, severe and frequent wheezing in early life is associated with a trajectory of poor lung function, which is associated with respiratory and non-respiratory health outcomes in later adulthood, including high-risk chronic obstructive pulmonary disease and high-risk cardiovascular and cerebrovascular events in middle age. However, recurrent preschool wheezing, which is defined as two or more wheezing episodes in children younger than 6 years, excluding bronchiolitis, is highly heterogeneous in etiology and prognosis and poses significant diagnostic and therapeutic challenges for pediatricians. Thirty Chinese experts majoring in pediatric pulmonology and epidemiology were invited to write this practical consensus on the diagnosis and treatment of recurrent wheezing in preschool children on the basis of evidence collection and experience. Elucidation and reviews were conducted using electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang databases. We used variations in terms for "wheezing", "asthma", "wheezing bronchitis", "preschool", "children", and "pediatric". The etiology, evaluation, management of acute wheezing exacerbation, and strategy of long-term anti-inflammatory therapy in recurrent preschool wheezing are highlighted. The most common causes of preschool wheezing are virus-induced wheezing and asthma (typical wheezing), some of which require long-term anti-inflammatory therapy. Some other children had identifiable underlying diseases (atypical wheezing). On the basis of the confirmation of wheezing, the underlying diseases and phenotypes of typical wheezing should be carefully investigated. For acute wheezing, inhaled short-acting β₂-agonists are the first-line agents, and systemic corticosteroids should be reserved only for severe cases. Routine use of azithromycin is not recommended in acute wheezing. The decision to initiate long-term anti-inflammatory therapy for recurrent preschool wheezing should be based on a comprehensive evaluation of clinical risk indicators and treatable traits such as type 2 inflammation. Immunomodulators such as bacterial lysates may be considered for use in trials in preschool children with recurrent virus-induced wheezing. This symptom-based, phenotype-oriented consensus provides practical guidance for the individualized management of heterogeneous recurrent wheezing in preschool children. Further studies are needed to identify clinical risk factors and biomarkers for persistent wheezing and asthma. More appropriate long-term treatment regimens should also be explored.

PMID 43050032
阅读全文 →
PubMedFrontiers in medicine2026-11-17

Vanishing bile duct syndrome reports and recorded fatal outcomes in FAERS: a disproportionality analysis.

Yin Yi Y, Zhang Guiju G

Vanishing bile duct syndrome (VBDS) is a rare but life-threatening condition characterized by progressive destruction of intrahepatic bile ducts, often leading to cirrhosis and death. Large-scale pharmacovigilance studies systematically investigating VBDS reports, particularly those with reported fatal outcomes, remain scarce. We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2004 Q1-2025 Q4). VBDS reports were identified using the MedDRA preferred term "Vanishing bile duct syndrome" (Code 10054753). We applied four algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM). A positive signal required meeting criteria for all four methods simultaneously. For drugs meeting signal criteria, we further performed a two-dimensional cross-analysis by intersecting drugs with the highest total report counts and those with the highest death counts, to identify drugs appearing in both top-10 rankings. After deduplication, 19,588,161 unique adverse event reports were available, among which 997 reports coded as VBDS were identified. A death outcome was recorded in 193 reports (19.36%); this proportion reflects FAERS reporting patterns and should not be interpreted as VBDS-attributable mortality or a clinical case-fatality estimate. Disproportionality analysis identified 48 drugs meeting all four signal criteria. Notably, only carbamazepine explicitly mentioned VBDS in its FDA label, and merely 18 of the 48 drugs included the broader term "cholestasis". Through cross-analysis of total report counts and reported death counts, six drugs appeared in both top-10 ranking lists: ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, and celecoxib. This large-scale pharmacovigilance analysis of FAERS suggests the mention of VBDS among FDA product labels differs across drugs generating post-marketing safety signals, and that this difference warrants further regulatory and clinical evaluation. Six agents (ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, celecoxib) appeared in both top-10 ranking lists for total VBDS reports and reported death counts. Because these rankings are based on descriptive absolute FAERS report counts, these agents warrant further clinical and pharmacovigilance evaluation, particularly in patients with pre-existing risk factors for DILI. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than the evidence of causality.

PMID 43041357
阅读全文 →
PubMedInternational journal of pharmaceutics2026-11-16

Mucoadhesive dual-extrusion 3D-printed bilayer buccal films for enhanced paediatric delivery of azithromycin.

Fratini Costanza C, Abruzzo Angela A, D'Abbrunzo Ilenia I, Parolin Carola C et al.

Paediatric administration of azithromycin (AZT) is often limited by low bioavailability (∼37%) and poor patient compliance associated with conventional oral dosage forms. In this study, novel mucoadhesive bilayer buccal films were developed using a dual-extrusion 3D printing strategy to enhance transmucosal delivery and ensure unidirectional drug diffusion. The hydrophilic mucoadhesive layer was formulated using sodium hyaluronate and Soluplus®, incorporating either crystalline AZT, crystalline AZT with formulation enhancers (bile salts or sucrose palmitate), or a co-amorphous system, i.e., AZT-caprylic acid (AZT-ACPL). Rheological investigations showed optimal thixotropic recovery of the hydrogel inks for semi-solid extrusion. In addition, the bilayer films were fabricated in a single-step, continuous process using a combined dual-extrusion 3D printing system, where a flexible hydrophobic polycaprolactone backing layer was deposited via melt-based extrusion to prevent salivary wash-out and promote unidirectional drug diffusion. Solid-state analyses (XRPD, FTIR, SEM) showed structural component integrity and predominantly amorphous, highly homogeneous drug dispersion of AZT-ACPL in the loaded matrix. Incorporating the co-amorphous AZT-ACPL significantly boosted maximum water uptake compared to its crystalline counterpart. Ex-vivo permeation studies across porcine oesophageal mucosa demonstrated superior mucosal transport for the co-amorphous formulation, achieving ∼ 18% cumulative permeation after 6 h: more than 3-fold enhancement in permeation compared to crystalline AZT formulations and powder drug control. Ex-vivo mechanical testing demonstrated effective mucosal adhesion while the protective backing layer sustained mucosal residence for over 4 h by shielding the hydrogel from erosion. Overall, this dual-extrusion 3D printing technology holds the potential to offer a robust, and customizable strategy for personalized transmucosal drug delivery.

PMID 43039123
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多azithromycin